Novartis Vaccines & Diagnostics, Gmbh

Novartis Ag

Chiron Corporation

Other

Glaxosmithkline Biologicals Sa

Universaity of Stellenbosch

Susan Barnett

Jan Zur Megede

Indresh K Srivastava

Ying Lian

Victoria A Sharma

Rino Rappuoli

Karin Hartog

Mark J Selby

Gillis Otten

Catherine Greer

Susan Engelbrecht

Vega Masignani

Maria Scarselli

Thomas W Dubensky, Jr

John M Polo

Christopher I Walker

Ilya V Frolov

Hong Liu

David A Driver

Eric J Martin

Barbara Capecchi

Jason P Gardner

Estrelita Janse Van Rensburg

Thomas J Scriba

Andrew John Geall

Derek T O'Hagan

John J Donnelly

Michael Vajdy

Antu Dey

Jeffrey Ulmer

Estrelita Janse Van Rensberg

Weiguo Zhai

Derek O'hagan

This invention generally relates to immunogenic compositions that comprise an RNA component and a polypeptide component. Immunogenic compositions that deliver antigenic epitopes in two different forms&#x2014;a first epitope from a pathogen, in RNA-coded form; and a second epitope from the same pathogen, in polypeptide form&#x2014;are effective in inducing immune response to the pathogen. The invention also relates to a kit comprising an RNA-based priming composition and a polypeptide-based boosting composition. The kit may be used for sequential administration of the priming and the boosting compositions.

Immunogenic compositions and uses thereof

The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.

HIV-1 south african subtype C env proteins

The present invention relates to immunogenic complexes formed between polyanionic carbomers and Env polypeptides. Uses of the immunogenic complexes in applications including inducing an immune response and immunization generally are described. Methods of forming and manufacture of the immunogenic complexes are also described. The present invention also relates to immunogenic compositions including low viscosity, polyanionic carbomers and Env polypeptides. Uses of such immunogenic compositions in applications including inducing an immune response and immunization generally are described. Methods of manufacture of such immunogenic compositions are also described.

Immunogenic complexes of polyanionic carbomers and Env polypeptides and methods of manufacture and use thereof

Compositions and methods are provided for Eukaryotic Layered Vector Initiation Systems andreplicon particles for introducing heterologous sequences into cells for generating immune responses.

Compositions and methods for generating an immune response utilizing alphavirus-based vector systems

Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides.

Method of generating an immune response in a subject using fusion proteins comprising CD4 minimal modules and HIV Tat scaffold polypeptides that are capable of binding to the HIV envelope and exposing cryptic neutralization epitopes

Provided herein are HIV vaccines comprising HIV polypeptide-encoding DNA adsorbed to PLG and/or HIV proteins. Also provided are methods of using these vaccines to generate immune responses in a subject.

HIV vaccine formulations

Fusion proteins comprising CD4 minimal modules that bind to HIV Env polypeptides in a non-CD4 backbone are described. Also described are complexes of these fusion proteins with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.

Method for generating immune responses utilizing nucleic acids encoding fusion proteins comprising CD4 minimal modules and invasin polypeptides that are capable of binding to the HIV envelope and exposing cryptic neutralization epitopes

The present invention relates to polynucleotides encoding immunogenic HIV type C Gag- and/or Env-containing polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of Gag- and/or Env-containing proteins are also described.

Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof

Env-CD4 polypeptide complexes and hybrids that expose cryptic epitopes important in virus neutralization are disclosed. Methods of diagnosis, treatment and prevention using the polypeptides are also provided.

Method of inducing an antiviral immune response against HIV-1 utilizing chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics

The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polynucleotides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.

Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides, and uses thereof

Env-CD4 polypeptide complexes and hybrids that expose cryptic epitopes important in virus neutralization are disclosed. Method of diagnosis, treatment and prevention using the polypeptides are also provided.

Chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics that are capable of inducing neutralizing antibody responses against cryptic Env epitopes

Fusion proteins comprising CD4 minimal modules and invasin polypeptides that are capable of binding to the HIV envelope and exposing cryptic neutraliziation epitopes

Provided herein are small molecule CDmimetics effective to bind to HIV Env proteins. A CDmimetic of the invention, when bound to an Env protein, is effective to induce a conformational change in the Env protein such that cyptic epitopes on the Env protein are exposed. Also provided herein are related methods of identifying and using such small molecule CDmimetics, for example, to elicit an immune response in a subject upon administration.

Env polypeptide complexes and methods of use

The present disclosure relates to vectors comprising polynucleotide sequences that encode HIV polypeptides. In particular, the disclosure relates polycistronic vector constructs comprising sequences that encode HIV polypeptides as a single polyprotein. Compositions comprising these vectors and sequences along with methods of using these vectors and sequences are also disclosed.

Polycistronic HIV vector constructs

The present invention relates to the efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression cassettes encoding the HIV Gag-containing polypeptides are described, as are uses of the expression cassettes in applications including DNA immunization, generation of packaging cell lines, and production of Env-, tat- or Gag-containing proteins. The invention provides methods of producing Virus-Like Particles (VLPs), as well as, uses of the VLPs including, but not limited to, vehicles for the presentation of antigens and stimulation of immune response in subjects to whom the VLPs are administered.

Growing community of inventors

San Francisco, CA, United States of America

Susan Barnett